Read this company snapshot
Daily valuation snapshot
Niagen Bioscience, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $2.69
- Market capitalization (USD)
- $212,848,945.38
- Price / earnings (TTM)
- 13.31
- Price / book
- 2.58
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research NAGE in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research NAGE in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing NAGE with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $2.69 |
| Market capitalization (USD) | $212,848,945.38 |
| Price / earnings (TTM) | 13.31 |
| Price / book | 2.58 |
No matching rows. Clear the filter to see all records.
Read NAGE's valuation metrics
Company size
Niagen Bioscience, Inc. Common Stock's recorded market capitalization is $212,848,945.38. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
NAGE's recorded P/E is 13.31: about $13.31 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
NAGE's recorded price-to-book ratio is 2.58. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Niagen Bioscience, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about NAGE. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow NAGE's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.